Louiza S. Velentzis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Louiza S. Velentzis has a total of 157 co-authors. Here are the top co-authors by number of shared publications:
Karen Canfell
School of Public Health, Faculty of Medicine and Health, The University of Sydney, Sydney 2006, NSW, Australia
12 shared publications- Karen Canfell
School of Public Health, The University of Sydney, Sydney, Australia
8 shared publications - Carolyn Nickson
The Daffodil Centre, The University of Sydney, A Joint Venture with Cancer Council NSW, Sydney 2006, NSW, Australia
7 shared publications - Megan A. Smith
The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia
6 shared publications Emily Banks
Affiliation National Centre for Epidemiology and Population Health, Research School of Population Health, Australian National University, Canberra, Australian Capital Territory, Australia
4 shared publications- Gregory Bruce Mann
The Breast Service, The Royal Melbourne Hospital, Parkville, Australia
4 shared publications
Latest Publications
- Open Access
- 19 March 2025
- Published by Elsevier in The Lancet Regional Health - Western Pacific
- Vol. 57, 101520
Risk-adjusted breast screening: an Australian perspective and considerations for the Western Pacific
- 19 March 2025
- Published by Elsevier in The Lancet Regional Health - Western Pacific
- Vol. 57, 101520
Open AccessRisk-adjusted breast screening: an Australian perspective and considerations for the Western Pacific
- Open Access
- 13 February 2025
- Published by Wiley in Australian and New Zealand Journal of Obstetrics and Gynaecology
- Vol. 65 (4) , 518-529
Participation in the National Cervical Screening Program Among Women Who Gave Birth in New South Wales, Australia by Place of Maternal Birth: A Data Linkage Analysis
Objective: High participation rates in the National Cervical Screening Program (NCSP) by all groups of women are required to ensure the equitable elimination of cervical cancer in Australia. In this study, we examine screening participation of overseas‐born women compared to Australian‐born women who gave birth. Design: Population‐based retrospective cohort study using linked health datasets. Setting and Participants: Women who gave birth in New South Wales between January 1, 2000 and June 30, 2017. Main Outcome Measures: Participation in the NCSP (≥ 1 cytology test) in the 3‐ and 5‐year periods prior to delivery by place of maternal birth, adjusted for multiple socio‐demographic and health characteristics. Results: Among the 1 332 669 mothers who gave birth over the study period, overall cervical screening participation in the 3‐ and 5‐year periods prior to delivery was 67.0% and 75.7%, respectively. Participation was lower for overseas‐born mothers compared to Australian‐born mothers for both the 3‐year (57.8% vs. 71.7%; adjusted odds ratio [aOR]: 0.51, 95% confidence interval [CI]: 0.50–0.51) and 5‐year (64.9% vs. 81.2%; aOR: 0.40, 95% CI: 0.40–0.40) participation periods. All groups of overseas‐born women had substantially lower screening participation compared to Australian‐born women, with the lowest relative 3‐year participation in mothers born in Southern/Central Asia (aOR: 0.30, 95% CI: 0.30–0.31), Oceania (aOR: 0.31, 95% CI: 0.30–0.32), North‐East Asia (aOR: 0.49, 95% CI: 0.48–0.50), and New Zealand (aOR: 0.49, 95% CI: 0.48–0.51). Conclusions: Overseas‐born women had around half the cervical screening participation in the period prior to birth compared to Australian‐born women. It is likely that opportunities to screen these under‐screened groups during the antenatal period, typically a time of repeated health services contact, are missed.
- 13 February 2025
- Published by Wiley in Australian and New Zealand Journal of Obstetrics and Gynaecology
- Vol. 65 (4) , 518-529
Open AccessParticipation in the National Cervical Screening Program Among Women Who Gave Birth in New South Wales, Australia by Place of Maternal Birth: A Data Linkage Analysis
Objective: High participation rates in the National Cervical Screening Program (NCSP) by all groups of women are required to ensure the equitable elimination of cervical cancer in Australia. In this study, we examine screening participation of overseas‐born women compared to Australian‐born women who gave birth. Design: Population‐based retrospective cohort study using linked health datasets. Setting and Participants: Women who gave birth in New South Wales between January 1, 2000 and June 30, 2017. Main Outcome Measures: Participation in the NCSP (≥ 1 cytology test) in the 3‐ and 5‐year periods prior to delivery by place of maternal birth, adjusted for multiple socio‐demographic and health characteristics. Results: Among the 1 332 669 mothers who gave birth over the study period, overall cervical screening participation in the 3‐ and 5‐year periods prior to delivery was 67.0% and 75.7%, respectively. Participation was lower for overseas‐born mothers compared to Australian‐born mothers for both the 3‐year (57.8% vs. 71.7%; adjusted odds ratio [aOR]: 0.51, 95% confidence interval [CI]: 0.50–0.51) and 5‐year (64.9% vs. 81.2%; aOR: 0.40, 95% CI: 0.40–0.40) participation periods. All groups of overseas‐born women had substantially lower screening participation compared to Australian‐born women, with the lowest relative 3‐year participation in mothers born in Southern/Central Asia (aOR: 0.30, 95% CI: 0.30–0.31), Oceania (aOR: 0.31, 95% CI: 0.30–0.32), North‐East Asia (aOR: 0.49, 95% CI: 0.48–0.50), and New Zealand (aOR: 0.49, 95% CI: 0.48–0.51). Conclusions: Overseas‐born women had around half the cervical screening participation in the period prior to birth compared to Australian‐born women. It is likely that opportunities to screen these under‐screened groups during the antenatal period, typically a time of repeated health services contact, are missed.
- Open Access
- 5 August 2024
- Published by Elsevier in Preventive Medicine Reports
- Vol. 45, 102849
Correlates of intention-to-attend and confirmed cervical screening attendance during the COVID-19 pandemic in Australia: Findings from Compass-PLUS, a prospective cohort study
- 5 August 2024
- Published by Elsevier in Preventive Medicine Reports
- Vol. 45, 102849
Open AccessCorrelates of intention-to-attend and confirmed cervical screening attendance during the COVID-19 pandemic in Australia: Findings from Compass-PLUS, a prospective cohort study
- Open Access
- 13 October 2023
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 12
A modelled analysis of the impact of COVID-19-related disruptions to HPV vaccination
COVID-19 disrupted school attendance in many countries, delaying routine adolescent vaccination against human papillomavirus (HPV) in some settings. We used Policy1-Cervix, a dynamic model simulating HPV transmission, natural history, vaccination, cervical screening, and diagnosis of HPV-related cancers, to estimate the impact on HPV-related cancers from disruptions to HPV vaccination in a high-income setting. A baseline scenario of no disruption to HPV vaccination was modelled, which assumed uptake of the nonavalent vaccine at the age of 12 by 82.4% of females and 75.5% of males, as is the coverage in Australia. Additional lifetime HPV-related cancer cases were calculated for three disruption scenarios affecting one birth cohort (2008; aged 12 in 2020) compared to the baseline scenario: (1) 1-year delay (no doses missed); (2) 1- to 7-year delay (slow catch-up); (3) no catch-up (herd effects only). A fourth scenario assumed no catch-up HPV vaccination for two birth cohorts, that is all individuals born in 2008 and in 2009 missed vaccination (worst-case scenario). Compared to 1532 HPV-related cancer cases estimated for the baseline no disruption scenario, we found a 1-year delay could result in ≤0.3% more HPV-related cancers (n = 4) but the increase would be greater if catch-up was slower (5%; n = 70), and especially if there was no catch-up (49%; n = 750). Additional cancers for a single missed cohort were most commonly cervical (23% of the additional cases) and anal cancers (16%) in females and oropharyngeal cancers in males (20%). In the worst-case scenario of two birth cohorts missing vaccination, ≤62% more HPV-related cancers would be diagnosed (n = 1892). In conclusion, providing catch-up of missed HPV vaccines is conducted, short-term delays in vaccinating adolescents are unlikely to have substantial long-term effects on cancer.
- 13 October 2023
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 12
Open AccessA modelled analysis of the impact of COVID-19-related disruptions to HPV vaccination
COVID-19 disrupted school attendance in many countries, delaying routine adolescent vaccination against human papillomavirus (HPV) in some settings. We used Policy1-Cervix, a dynamic model simulating HPV transmission, natural history, vaccination, cervical screening, and diagnosis of HPV-related cancers, to estimate the impact on HPV-related cancers from disruptions to HPV vaccination in a high-income setting. A baseline scenario of no disruption to HPV vaccination was modelled, which assumed uptake of the nonavalent vaccine at the age of 12 by 82.4% of females and 75.5% of males, as is the coverage in Australia. Additional lifetime HPV-related cancer cases were calculated for three disruption scenarios affecting one birth cohort (2008; aged 12 in 2020) compared to the baseline scenario: (1) 1-year delay (no doses missed); (2) 1- to 7-year delay (slow catch-up); (3) no catch-up (herd effects only). A fourth scenario assumed no catch-up HPV vaccination for two birth cohorts, that is all individuals born in 2008 and in 2009 missed vaccination (worst-case scenario). Compared to 1532 HPV-related cancer cases estimated for the baseline no disruption scenario, we found a 1-year delay could result in ≤0.3% more HPV-related cancers (n = 4) but the increase would be greater if catch-up was slower (5%; n = 70), and especially if there was no catch-up (49%; n = 750). Additional cancers for a single missed cohort were most commonly cervical (23% of the additional cases) and anal cancers (16%) in females and oropharyngeal cancers in males (20%). In the worst-case scenario of two birth cohorts missing vaccination, ≤62% more HPV-related cancers would be diagnosed (n = 1892). In conclusion, providing catch-up of missed HPV vaccines is conducted, short-term delays in vaccinating adolescents are unlikely to have substantial long-term effects on cancer.
- Open Access
- 19 April 2023
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 149 (11) , 8317-8325
Incidence profile of four major cancers among migrants in Australia, 2005–2014
Purpose: To compare the incidence profile of four major cancers in Australia by place of birth. Methods: In this retrospective population-based cohort study, the analysis included 548,851 residents diagnosed with primary colorectum, lung, female breast, or prostate cancer during 2005–2014. Incidence rate ratio (IRR) and 95% confidence intervals (CI) were calculated for migrant groups relative to Australian-born. Results: Compared with Australian-born residents, most migrant groups had significantly lower incidence rates for cancers of the colorectum, breast and prostate. The lowest rates of colorectal cancer were among males born in Central America (IRR = 0.46, 95% CI 0.29–0.74) and females born in Central Asia (IRR = 0.38, 95% CI 0.23–0.64). Males born in North-East Asia had the lowest rates of prostate cancer (IRR = 0.40, 95% CI 0.38–0.43) and females born in Central Asia had the lowest rates of breast cancer (IRR = 0.55, 95% CI 0.43–0.70). For lung cancer, several migrant groups had higher rates than Australian-born residents, with the highest rates among those from Melanesia (males IRR = 1.39, 95% CI 1.10–1.76; females IRR = 1.40, 95% CI 1.10–1.78). Conclusions: This study describes cancer patterns among Australian migrants, which are potentially helpful in understanding the etiology of these cancers and guiding the implementation of culturally sensitive and safe prevention measures. The lower incidence rates observed for most migrant groups may be maintained with continued emphasis on supporting communities to minimize modifiable risk factors such as smoking and alcohol consumption and participation in organized cancer screening programmes. Additionally, culturally sensitive tobacco control measures should be targeted to migrant communities with high lung cancer incidence rates.
- 19 April 2023
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 149 (11) , 8317-8325
Open AccessIncidence profile of four major cancers among migrants in Australia, 2005–2014
Purpose: To compare the incidence profile of four major cancers in Australia by place of birth. Methods: In this retrospective population-based cohort study, the analysis included 548,851 residents diagnosed with primary colorectum, lung, female breast, or prostate cancer during 2005–2014. Incidence rate ratio (IRR) and 95% confidence intervals (CI) were calculated for migrant groups relative to Australian-born. Results: Compared with Australian-born residents, most migrant groups had significantly lower incidence rates for cancers of the colorectum, breast and prostate. The lowest rates of colorectal cancer were among males born in Central America (IRR = 0.46, 95% CI 0.29–0.74) and females born in Central Asia (IRR = 0.38, 95% CI 0.23–0.64). Males born in North-East Asia had the lowest rates of prostate cancer (IRR = 0.40, 95% CI 0.38–0.43) and females born in Central Asia had the lowest rates of breast cancer (IRR = 0.55, 95% CI 0.43–0.70). For lung cancer, several migrant groups had higher rates than Australian-born residents, with the highest rates among those from Melanesia (males IRR = 1.39, 95% CI 1.10–1.76; females IRR = 1.40, 95% CI 1.10–1.78). Conclusions: This study describes cancer patterns among Australian migrants, which are potentially helpful in understanding the etiology of these cancers and guiding the implementation of culturally sensitive and safe prevention measures. The lower incidence rates observed for most migrant groups may be maintained with continued emphasis on supporting communities to minimize modifiable risk factors such as smoking and alcohol consumption and participation in organized cancer screening programmes. Additionally, culturally sensitive tobacco control measures should be targeted to migrant communities with high lung cancer incidence rates.
- Open Access
- 6 April 2023
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 12
A modelled evaluation of the impact of COVID-19 on breast, bowel, and cervical cancer screening programmes in Australia
Australia introduced COVID-19 infection prevention and control measures in early 2020. To help prepare health services, the Australian Government Department of Health commissioned a modelled evaluation of the impact of disruptions to population breast, bowel, and cervical cancer screening programmes on cancer outcomes and cancer services. We used the Policy1 modelling platforms to predict outcomes for potential disruptions to cancer screening participation, covering periods of 3, 6, 9, and 12 mo. We estimated missed screens, clinical outcomes (cancer incidence, tumour staging), and various diagnostic service impacts. We found that a 12-mo screening disruption would reduce breast cancer diagnoses (9.3% population-level reduction over 2020–2021) and colorectal cancer (up to 12.1% reduction over 2020–21), and increase cervical cancer diagnoses (up to 3.6% over 2020–2022), with upstaging expected for these cancer types (2, 1.4, and 6.8% for breast, cervical, and colorectal cancers, respectively). Findings for 6–12-mo disruption scenarios illustrate that maintaining screening participation is critical to preventing an increase in the burden of cancer at a population level. We provide programme-specific insights into which outcomes are expected to change, when changes are likely to become apparent, and likely downstream impacts. This evaluation provided evidence to guide decision-making for screening programmes and emphasises the ongoing benefits of maintaining screening in the face of potential future disruptions.
- 6 April 2023
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 12
Open AccessA modelled evaluation of the impact of COVID-19 on breast, bowel, and cervical cancer screening programmes in Australia
Australia introduced COVID-19 infection prevention and control measures in early 2020. To help prepare health services, the Australian Government Department of Health commissioned a modelled evaluation of the impact of disruptions to population breast, bowel, and cervical cancer screening programmes on cancer outcomes and cancer services. We used the Policy1 modelling platforms to predict outcomes for potential disruptions to cancer screening participation, covering periods of 3, 6, 9, and 12 mo. We estimated missed screens, clinical outcomes (cancer incidence, tumour staging), and various diagnostic service impacts. We found that a 12-mo screening disruption would reduce breast cancer diagnoses (9.3% population-level reduction over 2020–2021) and colorectal cancer (up to 12.1% reduction over 2020–21), and increase cervical cancer diagnoses (up to 3.6% over 2020–2022), with upstaging expected for these cancer types (2, 1.4, and 6.8% for breast, cervical, and colorectal cancers, respectively). Findings for 6–12-mo disruption scenarios illustrate that maintaining screening participation is critical to preventing an increase in the burden of cancer at a population level. We provide programme-specific insights into which outcomes are expected to change, when changes are likely to become apparent, and likely downstream impacts. This evaluation provided evidence to guide decision-making for screening programmes and emphasises the ongoing benefits of maintaining screening in the face of potential future disruptions.
- Open Access
- 22 March 2023
- Published by Wiley in International Journal of Cancer
- Vol. 152 (12) , 2528-2540
Female reproductive and hormonal factors and lung cancer mortality among never‐smokers: A prospective cohort study of 287 408 Chinese women
There is growing, but inconsistent evidence suggesting oestrogen may play a key role in lung cancer development, especially among never‐smoking women for whom lung cancer risk factors remain largely elusive. Using the China Kadoorie Biobank, a large‐scale prospective cohort with 302 510 women aged 30 to 79 years recruited from 10 regions in China during 2004 to 2008, we assessed the risk of lung cancer death among self‐reported never‐smoking women who were cancer‐free at baseline, in relation to age at menarche, age at menopause, time since menopause, prior use of oral contraceptives (OCP), number of livebirths, breastfeeding and age at first livebirth. Women were followed up to December 31, 2016 with linkage to mortality data. Hazard ratios (HR) and 95% confidence intervals (CI) were estimated using Cox regression, adjusting for key confounders including several socio‐demographic, environmental and lifestyle factors. Among 287 408 never‐smoking women, 814 died from lung cancer with a median follow‐up of 10.3 years. Women who had used OCP within 15 years prior to baseline had a significantly higher hazard of lung cancer death compared with never‐users: HR = 1.85 (95% CI: 1.14‐3.00) and risk increased by 6% with each additional year of use: HR = 1.06 (1.01‐1.10). Among parous women, the hazard of lung cancer death increased by 13% with each single livebirth: HR = 1.13 (1.05‐1.23); and among post‐menopausal women, the risk increased by 2% with each year since menopause: HR = 1.02 (1.01‐1.04). These results suggest that reproductive factors which were proxies for lower endogenous oestrogen level, for example, longer duration of OCP use, could play a role in lung cancer development.
- 22 March 2023
- Published by Wiley in International Journal of Cancer
- Vol. 152 (12) , 2528-2540
Open AccessFemale reproductive and hormonal factors and lung cancer mortality among never‐smokers: A prospective cohort study of 287 408 Chinese women
There is growing, but inconsistent evidence suggesting oestrogen may play a key role in lung cancer development, especially among never‐smoking women for whom lung cancer risk factors remain largely elusive. Using the China Kadoorie Biobank, a large‐scale prospective cohort with 302 510 women aged 30 to 79 years recruited from 10 regions in China during 2004 to 2008, we assessed the risk of lung cancer death among self‐reported never‐smoking women who were cancer‐free at baseline, in relation to age at menarche, age at menopause, time since menopause, prior use of oral contraceptives (OCP), number of livebirths, breastfeeding and age at first livebirth. Women were followed up to December 31, 2016 with linkage to mortality data. Hazard ratios (HR) and 95% confidence intervals (CI) were estimated using Cox regression, adjusting for key confounders including several socio‐demographic, environmental and lifestyle factors. Among 287 408 never‐smoking women, 814 died from lung cancer with a median follow‐up of 10.3 years. Women who had used OCP within 15 years prior to baseline had a significantly higher hazard of lung cancer death compared with never‐users: HR = 1.85 (95% CI: 1.14‐3.00) and risk increased by 6% with each additional year of use: HR = 1.06 (1.01‐1.10). Among parous women, the hazard of lung cancer death increased by 13% with each single livebirth: HR = 1.13 (1.05‐1.23); and among post‐menopausal women, the risk increased by 2% with each year since menopause: HR = 1.02 (1.01‐1.04). These results suggest that reproductive factors which were proxies for lower endogenous oestrogen level, for example, longer duration of OCP use, could play a role in lung cancer development.
- Open Access
A modelled analysis of the impact of COVID-19-related disruptions to HPV vaccination analysis
COVID-19 disrupted school attendance in many countries, delaying routine adolescent vaccination against human papillomavirus (HPV) in some settings. We used the ‘ Policy1-Cervix’ HPV model (natural history/vaccination/screening/HPV-related cancers), to estimate the impact on HPV-related cancers from disruptions to HPV vaccination in a high-income setting. Compared to no disruption (nonavalent vaccine uptake, age 12 [females:82.4%; males:75.5%] as in Australia), additional lifetime HPV-related cancer cases were calculated for three disruption scenarios affecting one birth cohort (2008): i) 1-year delay (no doses missed); ii) 1 to 7-year delay (slow catch-up); iii) no catch-up (herd effects only). A fourth scenario assumed no catch-up for two cohorts (2008,2009). We found a 1-year delay could result in ≤0.3% more HPV-related cancers (n=4) but the increase would be greater if catch-up was slower (5%; n=70), and especially if there was no catch-up (49%; n=750). Additional cancers for a single missed cohort were most commonly cervical (23%), oropharyngeal (males:20%) or anal (females:16%). In the worst-case scenario of two cohorts missing vaccination, ≤62% more HPV-related cancers would be diagnosed (n=1,892). In conclusion, providing catch-up of missed HPV vaccines is conducted, short-term delays in vaccinating adolescents are unlikely to have substantial long-term effects on cancer.
Open AccessA modelled analysis of the impact of COVID-19-related disruptions to HPV vaccination analysis
COVID-19 disrupted school attendance in many countries, delaying routine adolescent vaccination against human papillomavirus (HPV) in some settings. We used the ‘ Policy1-Cervix’ HPV model (natural history/vaccination/screening/HPV-related cancers), to estimate the impact on HPV-related cancers from disruptions to HPV vaccination in a high-income setting. Compared to no disruption (nonavalent vaccine uptake, age 12 [females:82.4%; males:75.5%] as in Australia), additional lifetime HPV-related cancer cases were calculated for three disruption scenarios affecting one birth cohort (2008): i) 1-year delay (no doses missed); ii) 1 to 7-year delay (slow catch-up); iii) no catch-up (herd effects only). A fourth scenario assumed no catch-up for two cohorts (2008,2009). We found a 1-year delay could result in ≤0.3% more HPV-related cancers (n=4) but the increase would be greater if catch-up was slower (5%; n=70), and especially if there was no catch-up (49%; n=750). Additional cancers for a single missed cohort were most commonly cervical (23%), oropharyngeal (males:20%) or anal (females:16%). In the worst-case scenario of two cohorts missing vaccination, ≤62% more HPV-related cancers would be diagnosed (n=1,892). In conclusion, providing catch-up of missed HPV vaccines is conducted, short-term delays in vaccinating adolescents are unlikely to have substantial long-term effects on cancer.
- Open Access
Breast Cancer Risk Assessment Tools for Stratifying Women into Risk Groups: A Systematic Review
Background: The benefits and harms of breast screening may be better balanced through a risk-stratified approach. We conducted a systematic review assessing the accuracy of questionnaire-based risk assessment tools for this purpose. Methods: Population: asymptomatic women aged ≥40 years; Intervention: questionnaire-based risk assessment tool (incorporating breast density and polygenic risk where available); Comparison: different tool applied to the same population; Primary outcome: breast cancer incidence; Scope: external validation studies identified from databases including Medline and Embase (period 1 January 2008–20 July 2021). We assessed calibration (goodness-of-fit) between expected and observed cancers and compared observed cancer rates by risk group. Risk of bias was assessed with PROBAST. Results: Of 5124 records, 13 were included examining 11 tools across 15 cohorts. The Gail tool was most represented (n = 11), followed by Tyrer-Cuzick (n = 5), BRCAPRO and iCARE-Lit (n = 3). No tool was consistently well-calibrated across multiple studies and breast density or polygenic risk scores did not improve calibration. Most tools identified a risk group with higher rates of observed cancers, but few tools identified lower-risk groups across different settings. All tools demonstrated a high risk of bias. Conclusion: Some risk tools can identify groups of women at higher or lower breast cancer risk, but this is highly dependent on the setting and population.
Open AccessBreast Cancer Risk Assessment Tools for Stratifying Women into Risk Groups: A Systematic Review
Background: The benefits and harms of breast screening may be better balanced through a risk-stratified approach. We conducted a systematic review assessing the accuracy of questionnaire-based risk assessment tools for this purpose. Methods: Population: asymptomatic women aged ≥40 years; Intervention: questionnaire-based risk assessment tool (incorporating breast density and polygenic risk where available); Comparison: different tool applied to the same population; Primary outcome: breast cancer incidence; Scope: external validation studies identified from databases including Medline and Embase (period 1 January 2008–20 July 2021). We assessed calibration (goodness-of-fit) between expected and observed cancers and compared observed cancer rates by risk group. Risk of bias was assessed with PROBAST. Results: Of 5124 records, 13 were included examining 11 tools across 15 cohorts. The Gail tool was most represented (n = 11), followed by Tyrer-Cuzick (n = 5), BRCAPRO and iCARE-Lit (n = 3). No tool was consistently well-calibrated across multiple studies and breast density or polygenic risk scores did not improve calibration. Most tools identified a risk group with higher rates of observed cancers, but few tools identified lower-risk groups across different settings. All tools demonstrated a high risk of bias. Conclusion: Some risk tools can identify groups of women at higher or lower breast cancer risk, but this is highly dependent on the setting and population.
- Open Access
- 31 January 2023
- Published by Elsevier in Tumour Virus Research
- Vol. 15, 200255
Exploring monitoring strategies for population surveillance of HPV vaccine impact using primary HPV screening
- 31 January 2023
- Published by Elsevier in Tumour Virus Research
- Vol. 15, 200255
Open AccessExploring monitoring strategies for population surveillance of HPV vaccine impact using primary HPV screening